{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:11:54Z","timestamp":1792177914468,"version":"4.4.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2014,8,23]],"date-time":"2014-08-23T00:00:00Z","timestamp":1408752000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s40263-014-0192-0","type":"journal-article","created":{"date-parts":[[2014,8,22]],"date-time":"2014-08-22T07:46:56Z","timestamp":1408693616000},"page":"835-854","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["Pregabalin: A Review of its Use in Adults with Generalized Anxiety Disorder"],"prefix":"10.1007","volume":"28","author":[{"given":"James E.","family":"Frampton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,23]]},"reference":[{"key":"192_CR1","first-page":"883","volume":"9","author":"DS Baldwin","year":"2013","unstructured":"Baldwin DS, Ajel K, Masdrakis VG, et al. Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr. 2013;9:883\u201392.","journal-title":"Neuropsychiatr"},{"issue":"2","key":"192_CR2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2165\/00023210-200923020-00002","volume":"23","author":"MA Katzman","year":"2009","unstructured":"Katzman MA. Current considerations in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(2):103\u201320.","journal-title":"CNS Drugs."},{"issue":"1","key":"192_CR3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1586\/14737175.2014.853617","volume":"14","author":"C Both","year":"2014","unstructured":"Both C, Kojda G, Lange-Asschenfeldt C. Pharmacotherapy of generalized anxiety disorder: focus and update on pregabalin. Expert Rev Neurother. 2014;14(1):29\u201338.","journal-title":"Expert Rev Neurother"},{"key":"192_CR4","unstructured":"Brown TA, O\u2019Leary TA, Barlow DH. Chapter 4. Generalized anxiety disorder. In: Barlow DH, editor. Clinical handbook of psychological disorders. 3rd ed. New York: Guilford Press; 2001. p. 154\u2013208. http:\/\/commonweb.unifr.ch\/artsdean\/pub\/gestens\/f\/as\/files\/4660\/21992_121827.pdf . Accessed 28 Apr 2014."},{"issue":"1","key":"192_CR5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/da.20257","volume":"25","author":"DL Hoffman","year":"2008","unstructured":"Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety. 2008;25(1):72\u201390.","journal-title":"Depress Anxiety"},{"key":"192_CR6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/da.1020","volume":"13","author":"RM Carter","year":"2001","unstructured":"Carter RM, Wittchen HU, Pfister H, et al. One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depress Anxiety. 2001;13:78\u201388.","journal-title":"Depress Anxiety"},{"issue":"1","key":"192_CR7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/da.20019","volume":"20","author":"C Hunt","year":"2004","unstructured":"Hunt C, Slade T, Andrews G. Generalized anxiety disorder and major depressive disorder comorbidity in the National Survey of Mental Health and Well-Being. Depress Anxiety. 2004;20(1):23\u201331.","journal-title":"Depress Anxiety"},{"issue":"5 Suppl 2","key":"192_CR8","first-page":"S9","volume":"106","author":"Y Aina","year":"2006","unstructured":"Aina Y, Susman JL. Understanding comorbidity with depression and anxiety disorders. J Am Osteopath Assoc. 2006;106(5 Suppl 2):S9\u201314.","journal-title":"J Am Osteopath Assoc"},{"issue":"10","key":"192_CR9","first-page":"917","volume":"30","author":"A Kanwar","year":"2013","unstructured":"Kanwar A, Malik S, Prokop LJ, et al. The association between anxiety disorders and suicidal behaviours: a systematic review and meta-analysis. Depress Anxiety. 2013;30(10):917\u201329.","journal-title":"Depress Anxiety"},{"issue":"11","key":"192_CR10","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1176\/appi.ajp.162.11.2116","volume":"162","author":"A Dumais","year":"2005","unstructured":"Dumais A, Lesage AD, Alda M, et al. Risk factors for suicide completion in major depression: a case\u2013control study of impulsive and aggressive behaviors in men. Am J Psychiatry. 2005;162(11):2116\u201324.","journal-title":"Am J Psychiatry"},{"key":"192_CR11","unstructured":"National Collaborating Centre for Mental Health. Generalized anxiety disorder in adults\u2014the NICE guideline on management in primary, secondary and community care. 2011. http:\/\/www.nice.org.uk\/nicemedia\/live\/13314\/52667\/52667.pdf . Accessed 7 May 2014."},{"key":"192_CR12","doi-asserted-by":"crossref","unstructured":"Hoge EA, Ivkovic A, Fricchione GL. Generalized anxiety disorder: diagnosis and treatment. BMJ. 2012;345:e7500. doi: 10.1136\/bmj.e7500 .","DOI":"10.1136\/bmj.e7500"},{"issue":"4","key":"192_CR13","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/15622970802465807","volume":"9","author":"B Bandelow","year":"2008","unstructured":"Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive\u2013compulsive and post-traumatic stress disorders\u2014first revision. World J Biol Psychiatry. 2008;9(4):248\u2013312.","journal-title":"World J Biol Psychiatry"},{"issue":"4","key":"192_CR14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.4088\/JCP.v69n0415","volume":"69","author":"SG Hoffman","year":"2008","unstructured":"Hoffman SG, Smits JAJ. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry. 2008;69(4):621\u201332.","journal-title":"J Clin Psychiatry"},{"key":"192_CR15","unstructured":"Uptodate\u00ae. Psychotherapy for generalized anxiety disorder. 2013. http:\/\/www.uptodate.com\/contents\/psychotherapy-for-generalized-anxiety-disorder . Accessed 27 Feb 2014."},{"issue":"2","key":"192_CR16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/13651501.2012.667114","volume":"16","author":"B Bandelow","year":"2012","unstructured":"Bandelow B, Sher L, Bunevicius R, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive\u2013compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012;16(2):77\u201384.","journal-title":"Int J Psychiatry Clin Pract"},{"key":"192_CR17","unstructured":"Pfizer Limited. Lyrica [25, 50, 75, 100, 200, 225 and 300\u00a0mg hard capsules; 20\u00a0mg\/mL oral solution]: EU summary of product characteristics. 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000546\/WC500046602.pdf . Accessed 26 Feb 2014."},{"key":"192_CR18","doi-asserted-by":"crossref","unstructured":"Frampton JE, Foster RH. Pregabalin: in the treatment of generalised anxiety disorder. [Erratum appears in CNS Drugs. 2007;21(6):481]. CNS Drugs. 2006;20(8):685\u201393 (discussion 94\u20135).","DOI":"10.2165\/00023210-200620080-00010"},{"issue":"Suppl 6","key":"192_CR19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.0013-9580.2004.455003.x","volume":"45","author":"E Ben-Menachem","year":"2004","unstructured":"Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45(Suppl 6):13\u20138.","journal-title":"Epilepsia"},{"issue":"1","key":"192_CR20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinthera.2007.01.013","volume":"29","author":"DM Tassone","year":"2007","unstructured":"Tassone DM, Boyce E, Guyer J, et al. Pregabalin: a novel \u03b3-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther. 2007;29(1):26\u201348.","journal-title":"Clin Ther"},{"issue":"8","key":"192_CR21","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/11634510-000000000-00000","volume":"26","author":"JA Mic\u00f3","year":"2012","unstructured":"Mic\u00f3 JA, Prieto R. Elucidating the mechanism of action of pregabalin: \u03b12\u03b4 as a therapeutic target in anxiety. CNS Drugs. 2012;26(8):637\u201348.","journal-title":"CNS Drugs"},{"issue":"10","key":"192_CR22","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/11536200-000000000-00000","volume":"49","author":"HN Bockbrader","year":"2010","unstructured":"Bockbrader HN, Wesche D, Miller R, et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49(10):661\u20139.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"192_CR23","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1177\/0091270009352087","volume":"50","author":"HN Bockbrader","year":"2010","unstructured":"Bockbrader HN, Radulovic LL, Posvar EL, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol. 2010;50(8):941\u201350.","journal-title":"J Clin Pharmacol"},{"issue":"46","key":"192_CR24","doi-asserted-by":"crossref","first-page":"17537","DOI":"10.1073\/pnas.0409066103","volume":"103","author":"MJ Field","year":"2006","unstructured":"Field MJ, Cox PJ, Stott E, et al. Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci USA. 2006;103(46):17537\u201342.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"192_CR25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.eplepsyres.2006.09.008","volume":"73","author":"CP Taylor","year":"2007","unstructured":"Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73(2):137\u201350.","journal-title":"Epilepsy Res"},{"issue":"7","key":"192_CR26","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1021\/jm049762l","volume":"48","author":"TR Bellioti","year":"2005","unstructured":"Bellioti TR, Capiris T, Ekhato IV, et al. Structure-activity relationships of pregabalin and analogues that target the alpha(2)-delta protein. J Med Chem. 2005;48(7):2294\u2013307.","journal-title":"J Med Chem"},{"issue":"2","key":"192_CR27","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1124\/jpet.111.180976","volume":"338","author":"SM Lotarski","year":"2011","unstructured":"Lotarski SM, Donevan S, El-Kattan A, et al. Anxiolytic-like activity of pregabalin in the Vogel conflict test in alpha2-1 (R217A) and alpha2-2 (R279A) mouse mutants. J Pharmacol Exp Ther. 2011;338(2):615\u201321.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"192_CR28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/0091270003251119","volume":"43","author":"EJ Randinitis","year":"2003","unstructured":"Randinitis EJ, Posvar EL, Alvey CW, et al. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol. 2003;43(3):277\u201383.","journal-title":"J Clin Pharmacol"},{"key":"192_CR29","first-page":"P18","volume":"69","author":"BW Corrigan","year":"2001","unstructured":"Corrigan BW, Pool WF, Posvar EL. Metabolic disposition of pregabalin in healthy volunteers [abstract no. PI-68]. Clin Pharmacol Ther. 2001;69:P18.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"192_CR30","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1176\/appi.ajp.160.3.533","volume":"160","author":"AC Pande","year":"2003","unstructured":"Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry. 2003;160(3):533\u201340.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"192_CR31","first-page":"240","volume":"23","author":"DE Feltner","year":"2003","unstructured":"Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003;23(3):240\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"9","key":"192_CR32","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/archpsyc.62.9.1022","volume":"62","author":"K Rickels","year":"2005","unstructured":"Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005;62(9):1022\u201330.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"192_CR33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/YIC.0b013e32831d7980","volume":"24","author":"S Kasper","year":"2009","unstructured":"Kasper S, Herman B, Nivoli G, et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol. 2009;24(2):87\u201396.","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"192_CR34","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/0269881111405360","volume":"26","author":"SJ Hadley","year":"2012","unstructured":"Hadley SJ, Mandel FS, Schweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J Psychopharmacol (Oxf). 2012;26(4):461\u201370.","journal-title":"J Psychopharmacol (Oxf)"},{"issue":"5","key":"192_CR35","doi-asserted-by":"crossref","first-page":"771","DOI":"10.4088\/JCP.v67n0511","volume":"67","author":"SA Montgomery","year":"2006","unstructured":"Montgomery SA, Tobias K, Zornberg GL, et al. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry. 2006;67(5):771\u201382.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"192_CR36","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/YIC.0b013e328350b133","volume":"27","author":"K Rickels","year":"2012","unstructured":"Rickels K, Shiovitz TM, Ramey TS, et al. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int Clin Psychopharmacol. 2012;27(3):142\u201350.","journal-title":"Int Clin Psychopharmacol"},{"issue":"5","key":"192_CR37","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1017\/S1461145713001557","volume":"17","author":"S Kasper","year":"2014","unstructured":"Kasper S, Iglesias-Garcia C, Schweizer E, et al. Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder. Int J Neuropsychopharmacol. 2014;17(5):685\u201395.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"192_CR38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/YIC.0b013e3282f0f0d7","volume":"23","author":"D Feltner","year":"2008","unstructured":"Feltner D, Wittchen H-U, Kavoussi R, et al. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol. 2008;23(1):18\u201328.","journal-title":"Int Clin Psychopharmacol"},{"issue":"5","key":"192_CR39","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1192\/bjp.bp.107.037788","volume":"193","author":"S Montgomery","year":"2008","unstructured":"Montgomery S, Chatamra K, Pauer L, et al. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry. 2008;193(5):389\u201394.","journal-title":"Br J Psychiatry"},{"issue":"2","key":"192_CR40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/01.jcp.0000155820.74832.b0","volume":"25","author":"RB Pohl","year":"2005","unstructured":"Pohl RB, Feltner DE, Fieve RR, et al. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol. 2005;25(2):151\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"Suppl 1","key":"192_CR41","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1016\/S0924-977X(00)80438-1","volume":"3","author":"AC Pande","year":"2000","unstructured":"Pande AC, Crockatt JG, Janney C, et al. Three randomised, placebo-controlled double-blind trials of pregabalin treatment of generalised anxiety disorder (GAD) [abstract no. P.3.025]. Int J Neuropsychopharmacol. 2000;3(Suppl 1):S344.","journal-title":"Int J Neuropsychopharmacol"},{"key":"192_CR42","unstructured":"European Medicines Agency. Product name: LYRICA. Product no. EMEA\/H\/C00546\/II0004. Scientific discussion. 2005. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion_-_Variation\/human\/000546\/WC500046605.pdf . Accessed 7 Mar 2014."},{"issue":"3","key":"192_CR43","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/YIC.0b013e3283249c7b","volume":"24","author":"DJ Stein","year":"2009","unstructured":"Stein DJ, Bruce Lydiard R, Herman BK, et al. Impact of gastrointestinal symptoms on response to pregabalin in generalized anxiety disorder: results of a six-study combined analysis. Int Clin Psychopharmacol. 2009;24(3):126\u201332.","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"192_CR44","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/YIC.0b013e32832dceb9","volume":"24","author":"SA Montgomery","year":"2009","unstructured":"Montgomery SA, Herman BK, Schweizer E, et al. The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia. Int Clin Psychopharmacol. 2009;24(4):214\u201322.","journal-title":"Int Clin Psychopharmacol"},{"issue":"6","key":"192_CR45","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.euroneuro.2008.01.004","volume":"18","author":"DJ Stein","year":"2008","unstructured":"Stein DJ, Baldwin DS, Baldinetti F, et al. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol. 2008;18(6):422\u201330.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"192_CR46","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1055\/s-0031-1291176","volume":"45","author":"MJ Boschen","year":"2012","unstructured":"Boschen MJ. Pregabalin: dose-response relationship in generalized anxiety disorder. Pharmacopsychiatry. 2012;45(2):51\u20136.","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"192_CR47","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1017\/S1461145709990460","volume":"13","author":"RB Lydiard","year":"2010","unstructured":"Lydiard RB, Rickels K, Herman B, et al. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol. 2010;13(2):229\u201341.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"9","key":"192_CR48","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1177\/070674371105600907","volume":"56","author":"MJ Boschen","year":"2011","unstructured":"Boschen MJ. A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder. Can J Psychiatry. 2011;56(9):558\u201366.","journal-title":"Can J Psychiatry"},{"issue":"4","key":"192_CR49","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1055\/s-2007-984400","volume":"40","author":"P Bech","year":"2007","unstructured":"Bech P. Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry. 2007;40(4):163\u20138.","journal-title":"Pharmacopsychiatry"},{"key":"192_CR50","doi-asserted-by":"crossref","unstructured":"Pollack MH, Walsh T, Cohn CK, et al. Pregabalin in GAD: efficacy in clinically-relevant subtypes [abstract no. NR224]. 157th Annual Meeting of the American Psychiatric Association; 1\u20136 May 2004; New York (NY).","DOI":"10.1176\/pn.39.4.0001"},{"issue":"Suppl 4","key":"192_CR51","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0924-977X(03)92176-6","volume":"13","author":"M Pollack","year":"2003","unstructured":"Pollack M. Pregabalin in generalized anxiety disorder: influence of subsyndromic depression [abstract no. P.3.056]. Eur Neuropsychopharmacol. 2003;13(Suppl 4):377.","journal-title":"Eur Neuropsychopharmacol"},{"key":"192_CR52","unstructured":"Montgomery SA, Rickels K, Bielski RJ. Pregabalin in GAD: speed of onset [abstract no. NR775]. 156th American Psychiatric Association Annual Meeting; 17\u201322 May 2003; San Francisco (CA)."},{"issue":"Suppl 4","key":"192_CR53","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0924-977X(03)92174-2","volume":"13","author":"SA Montgomery","year":"2003","unstructured":"Montgomery SA. Pregabalin in generalized anxiety disorder: speed of onset [abstract no. P.3.054]. Eur Neuropsychopharmacol. 2003;13(Suppl 4):376\u20137.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"15","key":"192_CR54","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1517\/14656566.7.15.2139","volume":"7","author":"SA Montgomery","year":"2006","unstructured":"Montgomery SA. Pregabalin for the treatment of generalised anxiety disorder. Expert Opin Pharmacother. 2006;7(15):2139\u201354.","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"192_CR55","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1185\/03007995.2013.820694","volume":"29","author":"S Montgomery","year":"2013","unstructured":"Montgomery S, Emir B, Haswell H, et al. Long-term treatment of anxiety disorders with pregabalin: a 1\u00a0year open-label study of safety and tolerability. Curr Med Res Opin. 2013;29(10):1223\u201330.","journal-title":"Curr Med Res Opin"},{"key":"192_CR56","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4137\/CMT.S1103","volume":"2","author":"S Montgomery","year":"2010","unstructured":"Montgomery S, Kasper S. Pharmacotherapy update: pregabalin in the treatment of generalized anxiety disorder. Clin Med Insights Ther. 2010;2:189\u2013202.","journal-title":"Clin Med Insights Ther"},{"key":"192_CR57","unstructured":"Boehm G, Hughes ATD. NDA: 21-446, 21-273, 21-724; drug: pregabalin (Lyrica). Review and evaluation of clinical data: NDA safety review. 2004. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2005\/021724s000_MedR_P2.pdf and http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2005\/021724s000_MedR_P3.pdf . Accessed 5 Apr 2014."},{"issue":"6","key":"192_CR58","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00228-012-1213-x","volume":"68","author":"G Zaccara","year":"2012","unstructured":"Zaccara G, Perucca P, Gangemi PF. The adverse event profile of pregabalin across different disorders: a meta-analysis. Eur J Clin Pharmacol. 2012;68(6):903\u201312.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"192_CR59","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1528-1167.2010.02966.x","volume":"52","author":"G Zaccara","year":"2011","unstructured":"Zaccara G, Gangemi P, Perucca P, et al. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011;52(4):826\u201336.","journal-title":"Epilepsia"},{"key":"192_CR60","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00213-005-0172-7","volume":"183","author":"I Hindmarch","year":"2005","unstructured":"Hindmarch I, Dawson J, Stanley N. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology (Berl). 2005;183:133\u201343.","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"192_CR61","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1185\/03007995.2012.684044","volume":"28","author":"J Cabrera","year":"2012","unstructured":"Cabrera J, Emir B, Dills D, et al. Characterizing and understanding body weight patterns in patients treated with pregabalin. Curr Med Res Opin. 2012;28(6):1027\u201337.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"192_CR62","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00228-010-0853-y","volume":"66","author":"S Schwan","year":"2010","unstructured":"Schwan S, Sundstrom A, Stjernberg E, et al. A signal for an abuse liability for pregabalin-results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol. 2010;66(9):947\u201353.","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"192_CR63","first-page":"605","volume":"110","author":"FA Filipetto","year":"2010","unstructured":"Filipetto FA, Zipp CP, Coren JS. Potential for pregabalin abuse or diversion after past drug-seeking behavior. J Am Osteopath Assoc. 2010;110(10):605\u20137.","journal-title":"J Am Osteopath Assoc"},{"issue":"3","key":"192_CR64","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4045\/tidsskr.08.0047","volume":"129","author":"F Chalabianloo","year":"2009","unstructured":"Chalabianloo F, Schj\u00f8tt J. Pregabalin and its potential for abuse [Article in Norwegian]. Tidsskr Nor Laegeforen. 2009;129(3):186\u20137.","journal-title":"Tidsskr Nor Laegeforen"},{"issue":"11","key":"192_CR65","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1478-7547-11-8","volume":"2013","author":"LS Miguel","year":"2013","unstructured":"Miguel LS, Miguel NS, In\u00eas M. A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal. Cost Eff Resour Alloc. 2013;2013(11):8.","journal-title":"Cost Eff Resour Alloc"},{"issue":"1","key":"192_CR66","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10198-009-0160-7","volume":"11","author":"M Vera-Llonch","year":"2010","unstructured":"Vera-Llonch M, Dukes E, Rejas J, et al. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective. Eur J Health Econ. 2010;11(1):35\u201344.","journal-title":"Eur J Health Econ"},{"key":"192_CR67","first-page":"157","volume":"4","author":"M Salas-Cansado De","year":"2012","unstructured":"De Salas-Cansado M, Olivares JM, \u00c1lvarez E, et al. Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain. Clinicoecon. 2012;4:157\u201368.","journal-title":"Clinicoecon"},{"issue":"6","key":"192_CR68","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s00127-012-0606-6","volume":"48","author":"M Salas-Cansado De","year":"2013","unstructured":"De Salas-Cansado M, \u00c1lvarez E, Olivares JM, et al. Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain. Soc Psychiatry Psychiatr Epidemiol. 2013;48(6):985\u201396.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"192_CR69","doi-asserted-by":"crossref","unstructured":"Carrasco JL, Olivares JM, \u00c1lvarez E, et al. Cost-effectiveness of pregabalin versus usual care in duloxetine-refractory out-patients with generalized anxiety disorder: an economic evaluation under medical usual practice in mental health centers [poster]. International Society for Pharmacoeconomics and Outcomes Research 12th Annual European Congress; 24\u201327 Oct 2009; Paris.","DOI":"10.1016\/S1098-3015(10)74756-2"},{"key":"192_CR70","doi-asserted-by":"crossref","unstructured":"Carrasco JL, Olivares JM, \u00c1lvarez E, et al. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI treatment: a cost-consequences analysis in medical practice in Spain [poster]. International Society for Pharmacoeconomics and Outcomes Research 16th Annual European Congress; 2\u20136 Nov 2013; Dublin.","DOI":"10.1016\/j.jval.2013.08.1401"},{"issue":"3","key":"192_CR71","first-page":"164","volume":"41","author":"JL Carrasco","year":"2013","unstructured":"Carrasco JL, \u00c1lvarez E, Olivares JM, et al. A comparative cost-analysis of initiating pregabalin or SSRI\/SNRI therapy in benzodiazepine-resistant patients with generalized anxiety disorder in Spain. Actas Esp Psiquiatr. 2013;41(3):164\u201374.","journal-title":"Actas Esp Psiquiatr"},{"key":"192_CR72","doi-asserted-by":"crossref","unstructured":"L\u00f6froth E, Myr\u00e9n KJ, Sandelin R. Cost impact of initiating pregabalin treatment in Swedish patients with generalized anxiety disorder [poster]. International Society for Pharmacoeconomics and Outcomes Research 13th Annual European Congress; 6\u20139 Nov 2010; Prague.","DOI":"10.1016\/S1098-3015(11)72889-3"},{"issue":"4","key":"192_CR73","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40273-013-0031-z","volume":"31","author":"I Mavranezouli","year":"2013","unstructured":"Mavranezouli I, Meader N, Cape J, et al. The cost effectiveness of pharmacological treatments for generalized anxiety disorder. Pharmacoeconomics. 2013;31(4):317\u201333.","journal-title":"Pharmacoeconomics"},{"key":"192_CR74","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2174\/1745017901208010158","volume":"8","author":"E \u00c1lvarez","year":"2012","unstructured":"\u00c1lvarez E, Carrasco JL, Olivares JM, et al. Broadening of generalized anxiety disorders definition does not affect the response to psychiatric care: findings from the observational ADAN study. Clin Pract Epidemiol Men Health. 2012;8:158\u201368.","journal-title":"Clin Pract Epidemiol Men Health"},{"issue":"3","key":"192_CR75","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1345\/aph.1Q405","volume":"46","author":"TM Wensel","year":"2012","unstructured":"Wensel TM, Powe KW, Cates ME. Pregabalin for the treatment of generalized anxiety disorder. Ann Pharmacother. 2012;46(3):424\u20139.","journal-title":"Ann Pharmacother"},{"issue":"7","key":"192_CR76","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0149-2918(08)80047-1","volume":"30","author":"E Spina","year":"2008","unstructured":"Spina E, Santoro V, D\u2019Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther. 2008;30(7):1206\u201327.","journal-title":"Clin Ther"},{"key":"192_CR77","unstructured":"Parke-Davis Div of Pfizer Inc. Lyrica (pregabalin) capsules, oral solution: US prescribing information. 2013. http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=561 . Accessed 24 Jun 2014."},{"issue":"1","key":"192_CR78","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.euroneuro.2013.10.015","volume":"24","author":"S Kasper","year":"2014","unstructured":"Kasper S, Brasser M, Schweizer E, et al. How well do randomized controlled trial data generalize to \u2018real-world\u2019 clinical practice settings? A comparison of two generalized anxiety disorder studies. Eur Neuropsychopharmacol. 2014;24(1):125\u201332.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"192_CR79","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1017\/S1461145712000922","volume":"16","author":"E Holsboer-Trachsler","year":"2013","unstructured":"Holsboer-Trachsler E, Prieto R. Effects of pregabalin on sleep in generalized anxiety disorder. Int J Neuropsychopharmacol. 2013;16(4):925\u201336.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"7","key":"192_CR80","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1056\/NEJMcp022342","volume":"351","author":"GL Fricchione","year":"2004","unstructured":"Fricchione GL. Generalized anxiety disorder. N Engl J Med. 2004;351(7):675\u201382.","journal-title":"N Engl J Med"},{"issue":"2","key":"192_CR81","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/YIC.0b013e328341bb4a","volume":"26","author":"M Samuel","year":"2011","unstructured":"Samuel M, Zimovetz EA, Gabriel Z, et al. Efficacy and safety of treatments for refractory generalized anxiety disorder: a systematic review. Int Clin Psychopharmacol. 2011;26(2):63\u20138.","journal-title":"Int Clin Psychopharmacol"},{"key":"192_CR82","doi-asserted-by":"crossref","unstructured":"Bandelow B, Wedekind D, Leon T. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother. 2007;7(7):769-81.","DOI":"10.1586\/14737175.7.7.769"},{"issue":"8","key":"192_CR83","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/0269881107076996","volume":"21","author":"RB Hidalgo","year":"2007","unstructured":"Hidalgo RB, Tupler LA, Davidson JR. An effect size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol. 2007;21(8):864\u201372.","journal-title":"J Psychopharmacol"},{"key":"192_CR84","unstructured":"Taylor TN, Feltner DE, Goodrich J. Pregabalin improves patient-reported work productivity in patients with GAD (abstract no. NR812). American Psychiatric Association 2003 Annual Meeting; 17\u201322 May 2003; San Francisco (CA)."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-014-0192-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-014-0192-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-014-0192-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T05:48:00Z","timestamp":1565761680000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-014-0192-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,23]]},"references-count":84,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["192"],"URL":"https:\/\/doi.org\/10.1007\/s40263-014-0192-0","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,23]]}}}